Table 1.
Compound | Cancer Type/Cell Line | Time Point (h) | IC50 | Reference |
---|---|---|---|---|
Hesperetin | Myeloid | 24 | 500 ± 100 µM | [222] |
Naringenin | Lymphoid | 48 | 164.9 ± 21.83 µM | [222] |
EGCG | Breast T47D | 72 | 14.17 µM | [49] |
Prostrate LNCaP | 48 | 0.4 µM | [223] | |
Prostrate PC3 | 48 | 38.95 µM | [224] | |
Lung | 24 | 70 µM | [225] | |
Bladder | 70–80 µM | [226] | ||
Acute T-lymphoblastic leukemia (CCRF-CEM) | 16.04 ± 1.56 µM | [227] | ||
Quercetin | Bladder | 48 | 876.9 ± 13.1 µM | [222] |
Kaempferol | Bone | 24 | 148.4 µM | [222] |
Fisetin | Erythroid | 48 | 15 ± 2 µM | [222] |
Myricetin | Colon | 72 | 68.0 ± 20.4 µM | [222] |
Galangin | Liver | 24 | 100.4 ± 17.0 µM | [222] |
Casticin | Lung A549 | 48 | 0.4 µMol/L | [228] |
Actute T-lymphoblastic leukemia (CCRF-CEM) | 24 & 72 | 0.28 ± 0.02 µM | [227] | |
Leukemia K562 | 48 | 5.95 µM | [229] | |
Leukemia Kasumi-1 | 48 | 15.56 µM | [229] | |
Leukemia HL-60 | 48 | 4.82 µM | [229] | |
Apigenin | ER- breast | 24 | 60.4 ± 15.8 µM | [222] |
Chrysin | ER+ breast | 48 | 82.5 µM | [222] |
Luteolin | Lung | 72 | 35.9 ± 9.3 µM | [222] |
Baicalein | Stomach | 72 | 64.3 µM | [222] |
Tangertin | Melanoma | 48 | 0.3 µM | [222] |
Acacetin | Oral squamous HSC-3 | 24 | 25 µg/mL | [162] |
MCF7 | 24 | 26.4 ± 0.7 µM | [167] | |
Melanoma | 0.79 mM | [230] | ||
Flavopiridol | Bladder RT4/RTI12 | 24–72 | 150–350 nM | [231] |
Bladder T24/SUP | 24–72 | 1000 nM | [231] | |
GCT | 72 | 60–70 nM | [232] | |
SKOV, MCF-7, HeLa | 72 | 280–350 nM | [232] | |
Esophageal | 72 | 100–150 mM | [233] | |
HNSCC tumor xenografts | 10 weeks | 5 mg/kg/day | [234] | |
Hematopoietic SUDHL4 | 12 | 120 mMol/L | [235] | |
Prostrate PC3 | 12 | 203 mMol/L | [235] | |
Wogonin | Ovarian | 72 | 19.9 ± 1.2 µM | [222] |
Eupatorin | HeLa | 11.72 ± 2.86 µM | [236] | |
K562 | 4.29 ± 1.35 µM | [236] | ||
MCF7 | 16.61 ± 5.56 µM | [236] | ||
RPMI8226 | 4.77 ± 0.51 µM | [236] | ||
HL-60 | 14.09 ± 0.55 µM | [236] | ||
MOLT | 4.74 ± 0.43 µM | [236] | ||
MDA-MB-468 | 96 | 0.5 µM | [182] | |
MCF-7 | 96 | 50 µM | [182] | |
Cyanidin | HL-60 | 48 | 31.6 µM | [237] |
Pelargonidin | HL-60 | 48 | 85.2 µM | [237] |
Osteosarcoma U2OS | 15 µM | [200] | ||
HepG2 | 24 | 33 µM | [238] | |
Delphinidin | HepG2 | 24 | 77 µM | [238] |
HL-60 | 48 | 10.9 µM | [237] | |
Genistein | Hepatocellular Hepa1-6 | 24 | 20 µM | [239] |
Pancreatic Mia-PaCa2 | 24 | 20 µM | [240] | |
Pancreatic PANC-1 | 24 | 25 µM | [240] | |
Pancreatic H6C7 | 24 | 120 µM | [240] | |
Colorectal HCT 116 | 24 | 690 µM | [217] | |
Colorectal HCT 116 | 48 | 135 µM | [217] | |
Colorectal HCT 116 | 72 | 61 µM | [217] | |
Daidzein | Colorectal HT-29 | 48 | 200 µM | [241] |
MIA PaCa-2 | 48 | 200 µM | [241] | |
Ovarian SKOV3 [224] | 24 | 20 µM | [242] | |
BEL-7402 | 48 | 59.7 ± 8.1 µM | [243] |